Athersys (ATHX) Jumps After Being Granted FDA Orphan Drug Status
- Top 10 News for 4/27 - 4/30: iPhone Pushes Apple to Another Strong Quarter; PCE Slowdown Hits Q1 GDP; U.S. Auto Sale Lag in April
- Third Point Reveals 'Significant Stake' in Yum! (YUM) and New Position in Devon (DVN)
- Tesla (TSLA) Debuts New Powerwall Home Battery Product
- Analyst Calls Apple Watch a Bust (AAPL)
- CSX (CSX) Gains Ahead of Sohn Conference as Ackman Chatter Grows Louder
Athersys, Inc. (Nasdaq: ATHX) spikes on word it was granted FDA orphan drug stats for MPS-1 treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leaked Fannie (FNMA), Freddie (FMCC) Memo May Include a 'Bombshell', Dick Bove Says
- Durect (DRRX) PT Lifted to $3 at Cantor Fitzgerald on Solid Q1 and Multiple Catalysts
- Tesla (TSLA) Battery Pack Uneconomical, Says Generac (GNRC) CEO - CNBC
Create E-mail Alert Related CategoriesFDA, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!